Affinity Asset Advisors, LLC Theseus Pharmaceuticals, Inc. Transaction History

Affinity Asset Advisors, LLC

  • $735 Million
  • Q2 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023
BUY
$2.66 - $10.04 $426,882 - $1.61 Million
160,482 Added 66.8%
400,726 $1.08 Million
Q2 2023

Aug 14, 2023
BUY
$7.28 - $11.82 $1.03 Million - $1.68 Million
142,023 Added 144.6%
240,244 $2.24 Million
Q1 2023

May 15, 2023
BUY
$5.21 - $14.05 $511,731 - $1.38 Million
98,221 New
98,221 $872,000

Others Institutions Holding THRX

# of Institutions
2
Shares Held
1.03M
Call Options Held
0
Put Options Held
0
View Full List

About Theseus Pharmaceuticals, Inc.

THRX Quotes by TradingView
  • Ticker THRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,713,400
  • Description
  • Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...
More about THRX
Track This Portfolio

Track Affinity Asset Advisors, LLC Portfolio

Follow Affinity Asset Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Affinity Asset Advisors, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email